Genetics of Huntington's disease and related disorders

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 985-989

  Burgunder, Jean Marc ^a,b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b SICHUAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOREIN; KELL PROTEIN; MEMBRANE PROTEIN; PROLINE RICH TRANSMEMBRANE PROTEIN 2; PROTEIN; UNCLASSIFIED DRUG;

BENIGN HEREDITARY CHOREA; CHOREA-ACANTHOCYTOSIS; COGNITIVE DEFECT; GENE MUTATION; GENETIC ANALYSIS; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUNTINGTON CHOREA; HYPERTRANSLUCENT LUNG; MENTAL DISEASE; MOLECULAR PATHOLOGY; NEUROACANTHOCYTOSIS; ONSET AGE; PAROXYSMAL KINESIGENIC DYSKINESIA; PHENOTYPE; REVIEW; SPINOCEREBELLAR DEGENERATION; ANIMAL; CHOREA; DYSKINESIAS; GENETIC SCREENING; GENETICS; HUNTINGTON DISEASE; MUTATION; PROCEDURES; TRENDS;

ANIMALS; CHOREA; DYSKINESIAS; GENETIC TESTING; HUMANS; HUNTINGTON DISEASE; MUTATION;

EID: 84903792591     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.03.005     Document Type: Review

References (44)

1. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
2. M. Losekoot et al. EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease Eur. J. Hum. Genet. 21 2013 480 486
3. M. Ramos-Arroyo et al. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing J. Neurol. Neurosurg. Psychiatry 76 2005 337 342 (Pubitemid 40299120)
4. O.W. Quarrell et al. Discrepancies in reporting the CAG repeat lengths for Huntington's disease Eur. J. Hum. Genet. 20 2012 20 26
5. H.F. Harbo et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias Eur. J. Neurol. 16 2009 777 785
6. E.W. Almqvist et al. A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease Am. J. Hum. Genet. 64 1999 1293 1304 (Pubitemid 30468747)
7. E.W. Almqvist et al. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease Clin. Genet. 64 2003 300 309 (Pubitemid 37236130)
8. P.S. Harper et al. Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium J. Med. Genet. 37 2000 567 571 (Pubitemid 30604092)
9. S.J. Evans et al. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records J. Neurol. Psychiatry Neurosurg. 84 2013 1156 1160
10. R. Macleod et al. Recommendations for the predictive genetic test in Huntington's disease Clin. Genet. 83 2013 221 231
11. J.-M. Burgunder Recent advances in the management of choreas Ther. Adv. Neurol. Disord. 6 2013 117 127
12. G. Nicolas et al. Juvenile Huntington disease in an 18-month-old boy revealed by global developmental delay and reduced cerebellar volume Am. J. Med. Genet. A 155 2011 815 818
13. G. Koutsis et al. The challenge of juvenile Huntington disease: to test or not to test Neurology 80 2013 990 996
14. H. Lipe, and T. Bird Late onset Huntington disease: clinical and genetic characteristics of 34 cases J. Neurol. Sci. 276 2009 159 162
15. A. Killoran et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS Neurology 80 2013 2022 2027
16. J.M. Lee et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion Neurology 78 2012 690 695
17. L. Arning, and J.T. Epplen Genetic modifiers of Huntington's disease Future Neurol. 7 2012 93 109
18. E.M. Ramos et al. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset Neurogenetics 14 2013 173 179
19. J.L. Li et al. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study Am. J. Hum. Genet. 73 2003 682 687
20. J.L. Li et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study BMC Med. Genet. 7 2006 71
21. J. Gayan et al. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds Genet. Epidemiol. 32 2008 445 453
22. I. Munoz-Sanjuan, and G.P. Bates The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease J. Clin. Invest. 121 2011 476 483
23. R.H. Walker et al. Neurologic phenotypes associated with acanthocytosis Neurology 68 2007 92 98 (Pubitemid 46071891)
24. E. Hewer et al. McLeod myopathy revisited: more neurogenic and less benign Brain 130 2007 3285 3296 (Pubitemid 350209081)
25. R. Pagon et al. GeneReviews 1993 University of Washington Seattle, WA [Internet]
26. H.H. Jung et al. Neuroacanthocytosis syndromes Orphanet. J. Rare Dis. 6 2011 68
27. S.E. Holmes et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2 Nat. Genet. 29 2001 377 378 (Pubitemid 34326684)
28. M. Mahajnah et al. Benign hereditary chorea: clinical, neuroimaging, and genetic findings J. Child Neurol. 22 2007 1231 1234
29. G.J. Breedveld et al. Mutations in TITF-1 are associated with benign hereditary chorea Hum. Mol. Genet. 11 2002 971 979 (Pubitemid 34449784)
30. E.M. Valente et al. A second paroxysmal kinesigenic choreoathetosis locus (EKD2) mapping on 16q13-q22.1 indicates a family of genes which give rise to paroxysmal disorders on human chromosome 16 Brain 123 2000 2040 2045
31. X. Wang et al. Paroxysmal kinesigenic choreoathetosis: evidence of linkage to the pericentromeric region of chromosome 16 in four Chinese families Eur. J. Neurol. 17 2010 800 807
32. W.J. Chen et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia Nat. Genet. 43 2011 1252 1255
33. J.L. Wang et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias Brain 134 2011 3493 3501
34. R.C. Moore et al. Huntington disease phenocopy is a familial prion disease Am. J. Hum. Genet. 69 2001 1385 1388 (Pubitemid 33124219)
35. R.H. Walker Update on the non-Huntington's disease choreas with comments on the current nomenclature Tremor Other Hyperkinet. Mov. (N. Y.) 2 2012 pii: tre-02-49-211-1
36. E.J. Wild et al. Huntington's disease phenocopies are clinically and genetically heterogeneous Mov. Disord. 23 2008 716 720
37. M. Namekawa et al. Choreiform movements in spinocerebellar ataxia type 1 J. Neurol. Sci. 187 2001 103 106 (Pubitemid 32611663)
38. D.H. Geschwind et al. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia Am. J. Hum. Genet. 60 1997 842 850 (Pubitemid 27146492)
39. G. Koutsis et al. Genetic screening of Greek patients with Huntington's disease phenocopies identifies an SCA8 expansion J. Neurol. 259 2012 1874 1878
40. M. Wardle et al. Dentatorubral pallidoluysian atrophy in South Wales J. Neurol. Neurosurg. Psychiatry 79 2008 804 807 (Pubitemid 351914728)
41. M. Panas et al. Co-segregation of Huntington disease and hereditary spastic paraplegia in 4 generations Neurologist 17 2011 211 212
42. R.H. Roxburgh et al. The unique co-occurrence of spinocerebellar ataxia type 10 (SCA10) and Huntington disease J. Neurol. Sci. 324 2013 176 178
43. B. Zhou et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome Nat. Genet. 28 2001 345 349 (Pubitemid 32702423)
44. R.J. Torres et al. Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants Curr. Rheumatol. Rep. 14 2012 189 194